4/5CERO THERAPEUTICS HOLDINGS, INC. (CERO): Going-concern doubt

Market data

Price before filing: $13.42 (2025-04-14 close, split/dividend-adjusted)
Market cap at flag: $5.7M (2025-04-15) · Latest: $253,050 (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-01-15 to 2025-05-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. ● There is substantial doubt as to our ability to continue as a going concern. ● Our business is highly dependent on the success of our lead product candidate."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-K (period 2024-12-31)